HansBiomed Corporation (042520) — Capital Reinvestment Ratio
Latest as of September 2025:
0.37x
HansBiomed Corporation (042520) has a Capital Reinvestment Ratio of 0.37x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩1.21 Billion) in capital expenditures (₩448.85 Million). See HansBiomed Corporation free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.37x
Capex / Operating Cash Flow
Operating Cash Flow
₩1.21 Billion
KRW
Capital Expenditures
₩448.85 Million
KRW
Data as of
Sep 2025
Most recent filing
HansBiomed Corporation Capital Reinvestment Ratio (2012–2025)
This chart tracks HansBiomed Corporation's Capital Reinvestment Ratio across 10 annual periods.
Annual Capital Reinvestment Ratio for HansBiomed Corporation (2012–2025)
Year-by-year Capital Reinvestment Ratio for HansBiomed Corporation from 2012 to 2025. For live market cap and broader valuation context, see 042520 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 5.52x | ₩318.34 Million | ₩1.76 Billion | ▲ +243.2% |
| 2024 | 1.61x | ₩1.76 Billion | ₩2.83 Billion | ▲ +31.3% |
| 2020 | 1.23x | ₩5.75 Billion | ₩7.05 Billion | ▼ -39.3% |
| 2019 | 2.02x | ₩7.71 Billion | ₩15.56 Billion | ▲ +368.7% |
| 2018 | 0.43x | ₩5.20 Billion | ₩2.24 Billion | ▼ -81.5% |
| 2017 | 2.33x | ₩5.60 Billion | ₩13.05 Billion | ▲ +33.1% |
| 2015 | 1.75x | ₩3.47 Billion | ₩6.07 Billion | ▼ -70.9% |
| 2014 | 6.01x | ₩2.06 Billion | ₩12.39 Billion | ▲ +92.3% |
| 2013 | 3.13x | ₩2.33 Billion | ₩7.29 Billion | ▲ +1750.5% |
| 2012 | 0.17x | ₩1.50 Billion | ₩253.56 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow